<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627118</url>
  </required_header>
  <id_info>
    <org_study_id>15-156-3</org_study_id>
    <nct_id>NCT02627118</nct_id>
  </id_info>
  <brief_title>Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H</brief_title>
  <acronym>bisphenol-A</acronym>
  <official_title>Clinical Study To Elucidate The Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR When Compared to a Non-BPA Containing Dialyzer, the Nipro ELISIO-15H</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nipro Medical Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to identify hepatic enzyme and estrogen-dependent biochemical changes
      that occur when dialysis patients are treated with dialyzers known to leach BPA (Bisphenol-A)
      into the blood, such as the commercially available Fresenius F160NR, as compared with the
      same chemical evaluations in patients being treated with the non BPA containing Nipro
      Elisio-15H dialyzer. Evaluations of patient's chemistries will be obtained prior to and after
      2 months of standard dialysis treatments with each dialyzer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to elucidate any eventual biochemical changes, and in particular,
      the in vivo estrogenic activity of BPA (Bisphenol-A), when BPA is being leached into the
      circulation by the Fresenius 160NR dialyzer as opposed to the same biochemical changes when
      there is no BPA being leached, as with the non-BPA containing Nipro Elisio-15H dialyzer. The
      estrogen dependent biochemical end points in humans include free testosterone, sex hormone
      binding globulin (SHBG) and thyroid binding globulin (TBG).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">July 11, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPA Level Following 2 Months of Dialysis</measure>
    <time_frame>2 MONTHS OF TREATMENT</time_frame>
    <description>blood sampling of BPA (Bisphenol-A) in ng/mL following 2 months of dialysis with the Fresenius 160NR or the Nipro Elisio 15-H</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Dialyzer Comparison</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FRESENIUS 160NR</intervention_name>
    <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER</description>
    <arm_group_label>Dialyzer Comparison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIPRO ELISIO-15H</intervention_name>
    <description>2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER</description>
    <arm_group_label>Dialyzer Comparison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male ESRD patients 18 years or older

          -  Stable on hemodialysis for more than 3 months

          -  Stable hematocrit equal to or above 29 %

          -  Stable vascular access

          -  Stable anticoagulation

          -  No active infection

          -  Able to sign informed consent and able to participate in the study

          -  Medically stable

        Exclusion Criteria:

          -  Participation in another study which may interfere with the planned study

          -  Active infection

          -  Medical conditions which may interfere with the study (unstable cardiac status,
             chronic liver disease, active hepatitis as defined by elevated liver enzymes)

          -  Females (It is expected that potential changes in estrogenic activity that might be
             seen in patients exposed to BPA will be modest and would be masked by naturally
             occurring variability of estrogen activity in women at varying stages of gonadal
             activity (pre, post-menopausal, different points in menstrual cycle, eventual
             pregnancy, etc). Thus, limiting study to adult males will maximize the possibility of
             detecting any changes in estrogenic activity.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre A Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <reference>
    <citation>Murakami K, Ohashi A, Hori H, Hibiya M, Shoji Y, Kunisaki M, Akita M, Yagi A, Sugiyama K, Shimozato S, Ito K, Takahashi H, Takahashi K, Yamamoto K, Kasugai M, Kawamura N, Nakai S, Hasegawa M, Tomita M, Nabeshima K, Hiki Y, Sugiyama S. Accumulation of bisphenol A in hemodialysis patients. Blood Purif. 2007;25(3):290-4. Epub 2007 Jul 2.</citation>
    <PMID>17622711</PMID>
  </reference>
  <reference>
    <citation>Huang X, Huang J, Zhang L, Zhu Y, Li Y. A novel ERα-mediated reporter gene assay for screening estrogenic/antiestrogenic chemicals based on LLC-MK2 cells. Toxicol Mech Methods. 2014 Dec;24(9):627-32. doi: 10.3109/15376516.2014.945107. Epub 2014 Sep 26.</citation>
    <PMID>25045971</PMID>
  </reference>
  <reference>
    <citation>Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology. 2006 Jun;147(6 Suppl):S56-69. Epub 2006 May 11. Review.</citation>
    <PMID>16690810</PMID>
  </reference>
  <reference>
    <citation>Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, Melzer D. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008 Sep 17;300(11):1303-10. doi: 10.1001/jama.300.11.1303. Epub 2008 Sep 16.</citation>
    <PMID>18799442</PMID>
  </reference>
  <reference>
    <citation>Trasande L, Attina TM, Trachtman H. Bisphenol A exposure is associated with low-grade urinary albumin excretion in children of the United States. Kidney Int. 2013 Apr;83(4):741-8. doi: 10.1038/ki.2012.422. Epub 2013 Jan 9.</citation>
    <PMID>23302717</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>May 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2018</results_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Andre A. Kaplan</investigator_full_name>
    <investigator_title>MEDICAL DIRECTOR UCONN DIALYSIS CENTER</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dialyzer Comparison</title>
          <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dialyzer Comparison</title>
          <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White Non-Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BPA Level Following 2 Months of Dialysis</title>
        <description>blood sampling of BPA (Bisphenol-A) in ng/mL following 2 months of dialysis with the Fresenius 160NR or the Nipro Elisio 15-H</description>
        <time_frame>2 MONTHS OF TREATMENT</time_frame>
        <population>When data was collected, BPA level was not measureable in one patient (lab reported the presence of unidentified “interfering substance”) and that patient’s data was removed from final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dialyzer Comparison</title>
            <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
          </group>
        </group_list>
        <measure>
          <title>BPA Level Following 2 Months of Dialysis</title>
          <description>blood sampling of BPA (Bisphenol-A) in ng/mL following 2 months of dialysis with the Fresenius 160NR or the Nipro Elisio 15-H</description>
          <population>When data was collected, BPA level was not measureable in one patient (lab reported the presence of unidentified “interfering substance”) and that patient’s data was removed from final analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>following Fresenius 160NR dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.76" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>following 2 months of Nipro Elisio 15-H dialyzer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FRESENIUS OPTIFLUX 160NR</title>
          <description>2 MONTHS OF DIALYSIS WITH THE FRESENIUS OPTIFLUX 160NR</description>
        </group>
        <group group_id="E2">
          <title>NIPRO ELISIO-15H</title>
          <description>2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andre Kaplan, MD</name_or_title>
      <organization>UConn Health</organization>
      <email>kaplan@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

